Praxis Precision Medicines Provides Update on Essential3 and Corporate Update
Detailed price information for Praxis Precision Medicines Inc (PRAX-Q) from The Globe and Mail including charting and trades.
Informatica Named a Leader in the 2025 Gartner® Magic Quadrant™ for Augmented Data ...
Informatica (NYSE: INFA), a leader in enterprise AI-powered cloud data management, announced that Gartner, Inc. has once again recognized the company as a Leader in the 2025 Gartner® Magic Quadrant™ ...
Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights ...
Interim analysis of overall survival in potentially registrational phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer expected in late Q1/early Q2 2025 Top-line data readout of potentially ...
The Business & Financial Times on MSN9 天
Whoopro’s ‘Let’s Talk Digital’ drives innovation in digital marketing space
Whoopro, powered by Global Media Alliance (GMA), has once again set the stage for groundbreaking conversations in the digital marketing industry with the successful hosting of Let’s Talk Digital.This ...
Praxis: Still A 'Hold' Despite Interim Analysis Setback Of Ulixacaltamide
Financially stable with $469.5 million in cash, Praxis Precision Medicines can fund operations until 2028. Read why my rating ...
Clinical Trials Arena on MSN14 天
Praxis Precision continues with ET trial despite likely failure warning
US-based Praxis Precision has decided not to halt its Phase III trial examining its essential tremor (ET) therapy after an independent review insisted it would likely fail to meet its endpoints. An ...
Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor ...
Praxis Precision Medicines' ulixacaltamide study for essential tremor faces setback as IDMC recommends stopping for futility. Topline results expected in Q3 2025.
The Pharma Letter14 天
Praxis Precision tanks on negative ulixacaltamide news
Boston, USA-based biotech Praxis Precision Medicines has provided an update on the interim analysis for Study 1 of the Essential3 program of ulixacaltamide in essential tremor (ET), sending the firm’s ...
Analysts Are Bullish on Top Healthcare Stocks: uniQure (QURE), Revolution Medicines (RVMD)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on uniQure (QURE – Research Report), Revolution ...
康乐卫士九价HPV疫苗研发取得重大进展
公司表示，独立数据监查委员会（IDMC）确认：有效性结果满足方案预设的首次分析统计准则。公司九价HPV疫苗（女性适应症）国内Ⅲ期保护效力临床试验首次分析结果符合预期，标志着九价HPV疫苗临床研究工作取得重大进展。
康乐卫士：九价 HPV 疫苗Ⅲ期试验有效
【3 月 1 日，康乐卫士公告重大进展！】康乐卫士自主研发的重组九价人乳头瘤病毒疫苗（大肠埃希菌）（简称“九价 HPV 疫苗”）（女性适应症）国内Ⅲ期保护效力临床试验的独立数据监查委员会（IDMC）已完成首次分析揭盲、主要效力指标和安全性评估。公司已收到 IDMC 根据首次分析结果出具的建议书，该建议书指出试验的有效性结果满足方案预设的首次分析统计准则。
格隆汇 on MSN17 天
康乐卫士九价HPV疫苗(女性适应症)国内Ⅲ期临床揭盲
格隆汇3月1日｜康乐卫士公告，公司自主研发的重组九价人乳头瘤病毒（6/11/16/18/31/33/45/52/58型）疫苗（大肠埃希菌）（简称“九价HPV疫苗”）（女性适应症）国内Ⅲ期保护效力临床试验的独立数据监查委员会（IDMC）已完成首次分析揭盲、主要效力指标和安全性评估，公司已收到IDMC根据首次分析结果出具的建议书，该建议书指出试验的有效性结果满足方案预设的首次分析统计准则。